In this issue of PET Clinics, guest editors Drs. Frederik Giesel, Rodney Hicks, and Ken Herrmann bring their considerable expertise to the topic of Fibroblast Activation Protein Imaging. Fibroblast activation protein (FAP) represents one of the most exciting pan-cancer targets identified in recent decades and has generated both active research and rapid clinical adoption of diagnostic agents based on small molecule FAP inhibitor (FAPI) molecules. In this issue, top experts who have been actively involved in developing or researching the utility of these agents across a broad spectrum of diseases summarize the current evidence regarding clinical applications of FAP-based imaging probes for diagnosis and, potentially, also for therapy.
Contains 16 practice-oriented topics including fibroblast activation protein inhibitor (FAPI) PET imaging in pancreatic cancer; fibroblast activation protein inhibitor (FAPI) PET imaging in colorectal cancer; fibroblast activation protein inhibitor (FAPI) cardiac imaging; fibroblast activation protein inhibitor (FAPI) PET/CT in gastric cancer; and more.
Provides in-depth clinical reviews on fibroblast activation protein imaging, offering actionable insights for clinical practice.
Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. xii 7. CME Accreditation Page - p. xiii 8. Preface - p. xv 9. Advanced Fibroblast Activation Protein-Ligand Developments: FAP Imaging Agents: A Review of the Structural Requirements - p. 287 10. Fibroblast Activation Protein Inhibitor PET in Pancreatic Cancer - p. 295 11. The Diagnostic Value of Fibroblast Activation Protein Imaging in Hepatocellular Carcinoma and Cholangiocellular Carcinoma - p. 309 12. Fibroblast Activation Protein Inhibitor PET Imaging in Head and Neck Cancer - p. 315 13. Fibroblast Activation Protein Inhibitor-PET Imaging in Colorectal Cancer - p. 325 14. Fibroblast Activation Protein Inhibitor PET/CT in Gastric Cancer - p. 337 15. Current Status of Fibroblast Activation Protein Imaging in Gynecologic Malignancy and Breast Cancer - p. 345 16. Fibroblast Activation Protein Inhibitor (FAPI)-PET Imaging in Sarcoma - p. 353 17. Fibroblast Activation Protein Inhibitor Theranostics: The Case for Use in Sarcoma - p. 361 18. Radiation Therapy Planning Using Fibroblast Activation Protein Inhibitor - p. 369 19. Imaging Fibrosis - p. 381 20. Cardiac Applications of Fibroblast Activation Protein Imaging - p. 389 21. Fibroblast Activation Protein Inhibitor Theranostics: Preclinical Considerations - p. 397 22. Fibroblast Activation Protein Inhibitor Theranostics: Preclinical Combination Treatment - p. 409 23. Fibroblast Activation Protein Inhibitor Theranostics: Early Clinical Translation - p. 419 24. Current State of Clinical Trials and Regulatory Approvals with Fibroblast Activation Protein Targeting Interventions - p. 429
In this issue of PET Clinics, guest editors Drs. Frederik Giesel, Rodney Hicks, and Ken Herrmann bring their considerable expertise to the topic of Fibroblast Activation Protein Imaging. Fibroblast activation protein (FAP) represents one of the most exciting pan-cancer targets identified in recent decades and has generated both active research and rapid clinical adoption of diagnostic agents based on small molecule FAP inhibitor (FAPI) molecules. In this issue, top experts who have been actively involved in developing or researching the utility of these agents across a broad spectrum of diseases summarize the current evidence regarding clinical applications of FAP-based imaging probes for diagnosis and, potentially, also for therapy.
Contains 16 practice-oriented topics including fibroblast activation protein inhibitor (FAPI) PET imaging in pancreatic cancer; fibroblast activation protein inhibitor (FAPI) PET imaging in colorectal cancer; fibroblast activation protein inhibitor (FAPI) cardiac imaging; fibroblast activation protein inhibitor (FAPI) PET/CT in gastric cancer; and more.
Provides in-depth clinical reviews on fibroblast activation protein imaging, offering actionable insights for clinical practice.
Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. xii 7. CME Accreditation Page - p. xiii 8. Preface - p. xv 9. Advanced Fibroblast Activation Protein-Ligand Developments: FAP Imaging Agents: A Review of the Structural Requirements - p. 287 10. Fibroblast Activation Protein Inhibitor PET in Pancreatic Cancer - p. 295 11. The Diagnostic Value of Fibroblast Activation Protein Imaging in Hepatocellular Carcinoma and Cholangiocellular Carcinoma - p. 309 12. Fibroblast Activation Protein Inhibitor PET Imaging in Head and Neck Cancer - p. 315 13. Fibroblast Activation Protein Inhibitor-PET Imaging in Colorectal Cancer - p. 325 14. Fibroblast Activation Protein Inhibitor PET/CT in Gastric Cancer - p. 337 15. Current Status of Fibroblast Activation Protein Imaging in Gynecologic Malignancy and Breast Cancer - p. 345 16. Fibroblast Activation Protein Inhibitor (FAPI)-PET Imaging in Sarcoma - p. 353 17. Fibroblast Activation Protein Inhibitor Theranostics: The Case for Use in Sarcoma - p. 361 18. Radiation Therapy Planning Using Fibroblast Activation Protein Inhibitor - p. 369 19. Imaging Fibrosis - p. 381 20. Cardiac Applications of Fibroblast Activation Protein Imaging - p. 389 21. Fibroblast Activation Protein Inhibitor Theranostics: Preclinical Considerations - p. 397 22. Fibroblast Activation Protein Inhibitor Theranostics: Preclinical Combination Treatment - p. 409 23. Fibroblast Activation Protein Inhibitor Theranostics: Early Clinical Translation - p. 419 24. Current State of Clinical Trials and Regulatory Approvals with Fibroblast Activation Protein Targeting Interventions - p. 429
